Key Takeaways
- Cardinal Health increased fiscal-year adjusted EPS outlook to $10.70–$10.80, compared to prior guidance of $10.15–$10.35.
- Third-quarter adjusted EPS reached $3.17, surpassing the analyst consensus of $2.79.
- Total revenue climbed 11% to $60.9 billion, falling short of the $62.1 billion Wall Street forecast.
- Net profit decreased to $399 million from $506 million year-over-year, impacted by a $184 million goodwill impairment.
- CAH shares gained 1.6% during premarket trading on Thursday.
Cardinal Health delivered an upward revision to its annual profit expectations for the second consecutive time this fiscal year, capturing investor attention. Shares responded positively, advancing 1.6% in Thursday’s premarket session to reach $205.99.
The healthcare distributor now projects adjusted earnings between $10.70 and $10.80 per share for fiscal 2026. This represents a notable improvement from the February outlook range of $10.15 to $10.35. Wall Street analysts had been forecasting approximately $10.31 per share.
While the improved guidance bolstered investor sentiment, the quarterly performance itself presented a more complicated picture.
On the earnings front, adjusted EPS reached $3.17, significantly exceeding the $2.79 analyst estimate. This substantial beat provided meaningful upside to expectations.
However, the revenue performance painted a contrasting narrative. Overall sales increased 11% from the prior-year period to $60.9 billion, yet this trailed the $62.1 billion consensus estimate.
The pharmaceutical and specialty solutions division accounted for the bulk of growth, generating $56.1 billion in revenue—an 11% increase compared to the same quarter last year.
Meanwhile, the global medical products and distribution division struggled. Revenue in this segment remained essentially unchanged year-over-year, pressured by reduced distribution volumes.
Bottom Line Takes a Hit
Net earnings fell to $399 million from $506 million recorded in the comparable quarter a year earlier. The primary driver behind this decline was a $184 million pretax goodwill impairment charge.
This write-down related to Cardinal’s oncology practice alliance and its Integrated Oncology Network, a business the company acquired toward the end of 2024.
While goodwill impairments don’t represent actual cash outflows, they indicate that an acquired asset’s value has deteriorated below its initial purchase valuation. Such charges warrant investor scrutiny.
Evercore ISI analyst Elizabeth Anderson characterized the performance as “solid,” observing that the pharmaceutical revenue shortfall primarily stemmed from wholesale acquisition cost dynamics—a passthrough matter rather than an operational weakness.
Specialty Pharmaceuticals Drive Forward Outlook
Cardinal Health, alongside industry competitors Cencora and McKesson, continues benefiting from robust demand for higher-margin specialty pharmaceutical products. Medications addressing cancer treatment and autoimmune conditions represent an expanding portion of the distribution landscape.
The introduction of biosimilar alternatives for previously patented blockbuster medications is also contributing to volume expansion. These therapeutic areas enable distributors to extract greater margins compared to conventional generic medications.
Cardinal has been systematically broadening its specialty care presence through strategic acquisitions of physician practices and specialty distribution networks. The Integrated Oncology Network transaction exemplified this strategic approach.
This strategy hasn’t proceeded without obstacles—this quarter’s impairment charge demonstrates that reality. Nevertheless, management remains committed to this strategic trajectory.
The enhanced full-year guidance, marking the second upward revision in consecutive quarters, reflects management’s optimism regarding performance in the remaining fiscal period.
Cardinal Health’s fiscal third quarter concluded on March 31. At the time of reporting, the stock traded 1.6% higher in premarket activity at $205.99.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
